China News Service, Beijing, June 7th. At the annual meeting of the American Society of Clinical Oncology (ASCO) that opened on the 4th local time, Chinese scholars have received oral presentations on 17 studies. Among them, Chia Tai Tianqing’s Anluo is worthy of attention. Nicolas became China's first innovative drug to carry out a phase III clinical trial of solid tumor patients abroad with positive results.
Many industry experts said in an interview that the clinical research of related drugs represents the international recognition of Chinese innovative drugs.
ASCO Annual Conference is one of the largest and most academically authoritative clinical oncology conferences in the world, with important clinical guidance value.
In recent years, Chinese innovative drugs have continued to appear on the international stage. This time Anlotinib has become China’s first domestically-made innovative drug to carry out clinical trials for patients with solid tumors overseas. Its published APROMISS Phase III clinical results of a variety of advanced soft tissue sarcomas show that Compared with dacarbazine (the current US drug for the treatment of soft tissue sarcoma) control group, Anlotinib showed longer progression-free survival in the treatment of patients with advanced synovial sarcoma.
As the person in charge of this clinical trial in the United States, Professor Brian Fantai from the University of Washington gave an oral report at this ASCO annual meeting.
On the evening of the 5th, he made a video connection with Chinese experts and professors to introduce in detail the relevant data and situation of this clinical trial.
It is reported that, different from the general phase III clinical trials, the control group of this experiment did not use a placebo, but used the current American drug dacarbazine for the treatment of soft group sarcoma, and still achieved benign results, indicating that related drugs are treating such tumors. The huge potential contained in it.
The drug's product name is Fu Kewei, and it is a 1.1-type new drug independently developed by Chia Tai Tianqing Pharmaceutical Group, the largest member company of the Hang Seng Index stock China Biopharmaceutical (HK.01177).
It has been approved in China for the treatment of four major indications of non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer and medullary thyroid carcinoma.
In addition, the combination of Anlotinib and chemotherapy, PD-1, and PD-L1 is being widely deployed. At present, more than 20 clinical trials have entered phase II or phase III clinical trials.
Zhou Caicun, a professor at Shanghai Pulmonary Hospital, said that with the rise of China's pharmaceutical industry and the continuous research and development of innovative products, Chinese achievements will inevitably go to the world.
Anlotinib's pioneering "Chinese medicine for American patients" is a great encouragement to domestic experts.
Han Baohui, a professor at the Chest Hospital of Shanghai Jiaotong University, believes that China's current clinical research can already keep pace with the international level in some areas, and clinical research related to innovative drugs independently developed has been highly valued in the international academic community.
I believe that more evidence-based medicine from Chinese scholars will emerge in the future, and clinical treatment strategies will continue to be enriched.
Xie Chengrun, chairman of Chia Tai Tianqing Pharmaceutical Group and executive director of China Biopharmaceuticals, said that China's pharmaceutical innovation has gradually embarked on a road of rapid development with the efforts of the government, enterprises, and clinical experts. The success of the world can be said to be "a matter of course."
"In the future, we will further accelerate the pace of clinical development at the global level, and look forward to benefiting more patients in China and even the world." (End)